staphylococcus aureus
PolandDrugs containing this active substance
-
It is used for the prevention of recurrent respiratory tract infections in adults and in children over 3 years of age.
Form: tablets, sublingual
Active substance Dosage staphylococcus aureus 6 billion streptococcus pyogenes 6 billion klebsiella pneumoniae 6 billion haemophilus influenzae 6 billion streptococcus pneumoniae 6 billion glycine 43 mg ATC: J07AX
Manufacturer: Bruschettini S.r.I.
-
The vaccine is used for prophylaxis in the case of recurrent respiratory tract infections in children aged 2 to 14 years and in adults.
Form: suspension for injection
Active substance Dosage haemophilus influenzae 100 million cells staphylococcus aureus 500 million cells streptococcus pneumoniae 100 million cells moraxella catarrhalis 100 million cells staphylococcus epidermidis 500 million cells streptococcus pneumoniae 100 million cells klebsiella pneumoniae 100 million cells corynebacterium pseudodiphtheriticum 200 million cells escherichia coli 200 million cells streptococcus salivarius 100 million cells ATC: J07AX
Manufacturer: Institute of Biotechnology of Sera and Vaccines BIOMED S.A.
-
The vaccine is used prophylactically in cases of recurrent respiratory tract infections in children aged 2 to 14 years and in adults.
Form: suspension for injection
Active substance Dosage streptococcus salivarius 10 million cells streptococcus pneumoniae 10 million cells haemophilus influenzae 10 million cells staphylococcus epidermidis 50 mln. cells corynebacterium pseudodiphtheriticum 20 mln. cells escherichia coli 20 mln. cells staphylococcus aureus 50 mln. cells klebsiella pneumoniae 10 million cells moraxella catarrhalis 10 million cells streptococcus pyogenes 10 million cells ATC: J07AX
Manufacturer: Institute of Biotechnology of Sera and Vaccines BIOMED S.A.
-
The vaccine is used prophylactically to prevent recurrent upper respiratory tract infections in children (from 6 months of age), adolescents, and adults.
Form: drops nasal suspension
Active substance Dosage haemophilus influenzae 10 million cells streptococcus pneumoniae 10 million cells klebsiella pneumoniae 10 million cells staphylococcus aureus 50 mln. cells staphylococcus epidermidis 50 mln. cells corynebacterium pseudodiphtheriticum 20 mln. cells escherichia coli 20 million cells streptococcus pyogenes 10 million cells streptococcus salivarius 10 million cells moraxella catarrhalis 10 million cells ATC: J07AX
Manufacturer: Institute of Biotechnology of Sera and Vaccines BIOMED S.A.
-
The vaccine is used for the prevention of recurrent respiratory tract infections in children aged 2 to 14 years and in adults.
Form: suspension for injection
Active substance Dosage klebsiella pneumoniae 1 million cells staphylococcus aureus qs staphylococcus epidermidis up to 1 ml streptococcus salivarius 1 million cells streptococcus pneumoniae 1 million cells streptococcus pyogenes 1 million cells escherichia coli 2 million cells haemophilus influenzae 1 million cells corynebacterium pseudodiphtheriticum 2 million cells moraxella catarrhalis 1 million cells ATC: J07AX
Manufacturer: Biomed - Kraków Vaccine and Serum Manufacturing Plant